Hepatic granulomas and hepatic sarcoidosis.

Abstract:

:The causes of hepatic granulomas are numerous and their identification can be difficult. Sarcoidosis is a main cause of hepatic granulomas. The mechanisms that initiate the formation of sarcoid granulomas are unknown. This article discusses the pathology of hepatic sarcoidosis and hepatic granulomas.

journal_name

Clin Liver Dis

journal_title

Clinics in liver disease

authors

Valla DC,Benhamou JP

doi

10.1016/s1089-3261(05)70108-2

subject

Has Abstract

pub_date

2000-02-01 00:00:00

pages

269-85, ix-x

issue

1

eissn

1089-3261

issn

1557-8224

pii

S1089-3261(05)70108-2

journal_volume

4

pub_type

杂志文章,评审
  • Hepatitis C virus. The importance of viral heterogeneity.

    abstract::Although recent evidence indicates that the quasispecies nature of HCV constitutes a critical strategy for the virus to survive in the host, the mechanisms of viral persistence remain unknown. Similarly, the correlates of immune protection in a limited proportion of individuals who succeed in clearing HCV are still la...

    journal_title:Clinics in liver disease

    pub_type: 杂志文章,评审

    doi:10.1016/s1089-3261(05)70200-2

    authors: Farci P

    更新日期:2001-11-01 00:00:00

  • Liver transplantation for hepatocellular carcinoma: expanding frontiers and building bridges.

    abstract::Despite significant advances in nonsurgical treatments of hepatocellular carcinoma, these approaches rarely result in cure. Surgery remains the mainstay of curative therapy for hepatocellular carcinoma. Liver transplantation, in particular, has emerged as one of the most beneficial therapeutic modalities. Questions re...

    journal_title:Clinics in liver disease

    pub_type: 杂志文章

    doi:10.1016/j.cld.2011.03.005

    authors: Masuoka HC,Rosen CB

    更新日期:2011-05-01 00:00:00

  • Noncirrhotic portal hypertension.

    abstract::Noncirrhotic portal hypertension represents a heterogeneous group of conditions that have distinct clinical and hemodynamic features that often help distinguish them from cirrhosis. [figure: see text] The sites of portal flow resistance may not be precisely localized to one area of the hepatic lobule and may extend be...

    journal_title:Clinics in liver disease

    pub_type: 杂志文章,评审

    doi:10.1016/s1089-3261(05)70191-4

    authors: Molina E,Reddy KR

    更新日期:2001-08-01 00:00:00

  • Expanded criteria donors.

    abstract::The greatest challenge facing liver transplantation today is the shortage of donor livers. Demand far exceeds supply, and this deficit has driven expansion of what is considered an acceptable organ. The evolving standard has not come without costs, however, as each new frontier of expanded donor quality (i.e., advanci...

    journal_title:Clinics in liver disease

    pub_type: 杂志文章,评审

    doi:10.1016/j.cld.2014.05.005

    authors: Feng S,Lai JC

    更新日期:2014-08-01 00:00:00

  • Artificial liver support devices for fulminant liver failure.

    abstract::Artificial liver-support devices attempt to bridge patients with fulminant hepatic failure until either a suitable liver allograft is obtained for transplantation or the patient's own liver regenerates sufficiently to resume normal function. It is thought that toxins contribute to the clinical picture of fulminant hep...

    journal_title:Clinics in liver disease

    pub_type: 杂志文章,评审

    doi:10.1016/s1089-3261(05)70172-0

    authors: Sechser A,Osorio J,Freise C,Osorio RW

    更新日期:2001-05-01 00:00:00

  • Predictors of a favorable response to alpha interferon therapy for hepatitis C.

    abstract::The most consistently identified predictive factors for a response to both IFN-alpha monotherapy and IFN-alpha in combination with ribavirin are a low HCV RNA level, the absence of fibrosis, infection with HCV genotype 2 and 3, and a prolonged duration of treatment. In addition, an early response to IFN-alpha predicts...

    journal_title:Clinics in liver disease

    pub_type: 杂志文章,评审

    doi:10.1016/s1089-3261(05)70238-5

    authors: Barnes E,Webster G,Whalley S,Dusheiko G

    更新日期:1999-11-01 00:00:00

  • The natural history of chronic hepatitis C virus infection.

    abstract::In conclusion, the natural history of chronic HCV infection has not yet been fully defined. Current data suggest that the process runs an indolent course during the first two decades after initial infection, accounting for modest morbidity and mortality. Serious sequelae are more likely to emerge as the disease proces...

    journal_title:Clinics in liver disease

    pub_type: 杂志文章,评审

    doi:10.1016/s1089-3261(05)70323-8

    authors: Seeff LB

    更新日期:1997-11-01 00:00:00

  • Other potential medical therapies: the use of antiviral agents to investigate and treat primary ciliary cirrhosis.

    abstract::A human betaretrovirus has been characterized in patients with primary biliary cirrhosis (PBC) and the related mouse mammary tumor virus linked with autoimmune biliary disease in the NOD.c3c4 mouse model. Translational studies have been performed in patients who have PBC to investigate the role of viral infection in d...

    journal_title:Clinics in liver disease

    pub_type: 杂志文章,评审

    doi:10.1016/j.cld.2008.02.006

    authors: Mason AL,Wasilenko ST

    更新日期:2008-05-01 00:00:00

  • Cholestasis and alcoholic liver disease.

    abstract::Histologic cholestasis and clinical jaundice may be seen in all stages of alcoholic liver disease. In rare cases, isolated cholestasis without significant steatosis, hepatitis, or cirrhosis is identified in an alcoholic patient. The mechanisms of ethanol-induced cholestasis are not well studied but may involve compres...

    journal_title:Clinics in liver disease

    pub_type: 杂志文章,评审

    doi:10.1016/s1089-3261(05)70086-6

    authors: Tung BY,Carithers RL Jr

    更新日期:1999-08-01 00:00:00

  • The global epidemiology of hepatocellular carcinoma: present and future.

    abstract::The global risk of hepatocellular carcinoma (HCC) has been largely driven by hepatitis B virus (HBV) infection for the past century, along with hepatitis C virus (HCV), aflatoxin, excessive alcohol consumption, and obesity/diabetes. The dominant effect of HBV on global HCC risk should decline as the population vaccina...

    journal_title:Clinics in liver disease

    pub_type: 杂志文章,评审

    doi:10.1016/j.cld.2011.03.006

    authors: McGlynn KA,London WT

    更新日期:2011-05-01 00:00:00

  • Mechanisms of disease progression in NASH: new paradigms.

    abstract::The incidence of nonalcoholic fatty liver disease is increasing at an astonishing rate in the US population. Although only a small proportion of these patients develop steatohepatitis (NASH), those who do have a greater likelihood of developing end-stage liver disease and complications. Research on liver fibrosis and ...

    journal_title:Clinics in liver disease

    pub_type: 杂志文章,评审

    doi:10.1016/j.cld.2012.05.002

    authors: Bohinc BN,Diehl AM

    更新日期:2012-08-01 00:00:00

  • Liver disease caused by disorders of bile acid synthesis.

    abstract::Bile acid synthetic defects are uncommon disorders that cause progressive cholestatic liver disease that is often lethal in infancy or early childhood. Five specific primary defects have been described. Diagnosis is based on mass spectrometry of urine and serum. Pathogenesis of liver injury is related to persistent re...

    journal_title:Clinics in liver disease

    pub_type: 杂志文章,评审

    doi:10.1016/s1089-3261(05)70144-6

    authors: Bove KE

    更新日期:2000-11-01 00:00:00

  • Liver Transplantation and Bariatric Surgery: Best Approach.

    abstract::Obesity has become increasingly prevalent, and the number of obese patients in need of liver transplant is expected to continue to increase. In addition, liver disease due to nonalcoholic fatty liver disease is expected to become the leading cause of liver transplantation in the near future. However, obesity remains a...

    journal_title:Clinics in liver disease

    pub_type: 杂志文章,评审

    doi:10.1016/j.cld.2016.12.001

    authors: Suraweera D,Dutson E,Saab S

    更新日期:2017-05-01 00:00:00

  • Understanding and Treating Pruritus in Primary Biliary Cholangitis.

    abstract::Pruritus is a common symptom with primary biliary cholangitis. Research has focused on refining understanding of the neurohumoral pathways involved in transduction of pruritus from peripheral cutaneous receptors to the central nervous system, and identifying modulating drugs. Current treatments have variable efficacy ...

    journal_title:Clinics in liver disease

    pub_type: 杂志文章,评审

    doi:10.1016/j.cld.2018.03.005

    authors: Carrion AF,Rosen JD,Levy C

    更新日期:2018-08-01 00:00:00

  • Pharmacologic Management of Hepatic Encephalopathy.

    abstract::Pharmacologic management of hepatic encephalopathy includes a broad range of therapies. This article covers the specific mainstays of therapies, such as antimicrobials and laxatives, with an established evidence base. This article also covers newer modalities of therapies, such as fecal microbiota transplant, probioti...

    journal_title:Clinics in liver disease

    pub_type: 杂志文章,评审

    doi:10.1016/j.cld.2020.01.005

    authors: Mahpour NY,Pioppo-Phelan L,Reja M,Tawadros A,Rustgi VK

    更新日期:2020-05-01 00:00:00

  • Surgical Resection: Old Dog, Any New Tricks?

    abstract::Patients with hepatocellular carcinoma (HCC) have many treatment options. For patients with surgical indication, consideration of future liver remnant and the surgical complexity of the procedure is essential. A new 3-level complexity classification categorizing 11 liver resection procedures predicts surgical complexi...

    journal_title:Clinics in liver disease

    pub_type: 杂志文章,评审

    doi:10.1016/j.cld.2020.07.004

    authors: Kawaguchi Y,Lillemoe HA,Vauthey JN

    更新日期:2020-11-01 00:00:00

  • Contemporary assessment of hepatic fibrosis.

    abstract::Newer noninvasive tests have begun to replace liver biopsy for staging purposes. The clinician must evaluate these tools and apply them to individual patients. None of these modalities give the exact same staging of fibrosis as a liver biopsy, but they are excellent tools for risk stratification. Still, it should be r...

    journal_title:Clinics in liver disease

    pub_type: 杂志文章,评审

    doi:10.1016/j.cld.2014.09.007

    authors: Bonder A,Tapper EB,Afdhal NH

    更新日期:2015-02-01 00:00:00

  • Management of autoimmune and cholestatic liver disorders.

    abstract::The management of autoimmune and cholestatic liver disorders is a challenging area of hepatology. Autoimmune and cholestatic liver diseases represent a comparatively small proportion of hepatobiliary disorders, yet their appropriate management is of critical importance for patient survival. In this article, management...

    journal_title:Clinics in liver disease

    pub_type: 杂志文章

    doi:10.1016/j.cld.2009.02.011

    authors: Krok KL,Munoz SJ

    更新日期:2009-05-01 00:00:00

  • Endoscopic retrograde cholangiopancreatography in diagnosis and treatment of primary sclerosing cholangitis.

    abstract::Primary sclerosing cholangitis is characterized by progressive fibrosing obliteration of the biliary tract. In some cases the disease is restricted to the small bile ducts, but most patients develop fibrotic stenoses of the larger bile ducts. Despite advances in magnetic resonance cholangiography, in unclear cases end...

    journal_title:Clinics in liver disease

    pub_type: 杂志文章,评审

    doi:10.1016/j.cld.2010.03.010

    authors: Gotthardt D,Stiehl A

    更新日期:2010-05-01 00:00:00

  • Surveillance for hepatocellular carcinoma and early diagnosis.

    abstract::Good management of patients at risk for the development of hepatocellular carcinoma includes regular ultrasound surveillance, and aggressive management of lesions detected at ultrasound. Good radiology and good pathology are essential to the appropriate management of these small lesions. With good quality testing it i...

    journal_title:Clinics in liver disease

    pub_type: 杂志文章,评审

    doi:10.1016/j.cld.2007.08.011

    authors: Sherman M

    更新日期:2007-11-01 00:00:00

  • Hepatotoxicity of antibiotics and antifungals.

    abstract::Hepatotoxicity associated with any antibiotic is rare. With the wide-spread use of antimicrobial agents, however, hepatic injury is not an infrequent occurrence. Penicillins remain a widely used class of antimicrobials with a well defined record of low hepatotoxicity. The combination of clavulanate with amoxicillin ma...

    journal_title:Clinics in liver disease

    pub_type: 杂志文章,评审

    doi:10.1016/s1089-3261(03)00021-7

    authors: Thiim M,Friedman LS

    更新日期:2003-05-01 00:00:00

  • The international normalized ratio of prothrombin time in the model for end-stage liver disease score: a reliable measure.

    abstract::The Model for End-stage Liver Disease (MELD) has been demonstrated to be an excellent predictor of survival in patients who have end-stage liver disease. It is derived from the international normalized ratio (INR) of prothrombin time, serum creatinine, and serum total bilirubin. The major use of the MELD score is to p...

    journal_title:Clinics in liver disease

    pub_type: 杂志文章

    doi:10.1016/j.cld.2008.09.001

    authors: Kamath PS,Kim WR

    更新日期:2009-02-01 00:00:00

  • Management complexities of HIV/hepatitis C virus coinfection in the twenty-first century.

    abstract::Because of shared routes of transmission, hepatitis C virus (HCV) coinfection is common among HIV-infected persons. Because of the effectiveness of antiretroviral therapy, chronic HCV has now emerged as a major cause of morbidity and mortality in this population. Because chronic HCV is highly prevalent among HIV-infec...

    journal_title:Clinics in liver disease

    pub_type: 杂志文章,评审

    doi:10.1016/j.cld.2008.03.009

    authors: Lo Re V 3rd,Kostman JR,Amorosa VK

    更新日期:2008-08-01 00:00:00

  • The Management of Hepatitis B in Liver Transplant Recipients.

    abstract::Liver transplant (LT) is now an established indication for patients with chronic hepatitis B, mainly because of the development and use of hepatitis B immunoglobulin (HBIG) and oral antivirals for prophylaxis. The combination of low-dose HBIG and antivirals has been considered the standard prophylaxis regimen to preve...

    journal_title:Clinics in liver disease

    pub_type: 杂志文章,评审

    doi:10.1016/j.cld.2016.06.004

    authors: Saab S,Chen PY,Saab CE,Tong MJ

    更新日期:2016-11-01 00:00:00

  • Primary biliary cirrhosis: the future.

    abstract::The answers to these questions are key to understanding the pathogenesis of PBC. Although the study of PBC is significantly retarded by the lack of an adequate animal model, the molecular technology to address these issues is advancing rapidly. In addition, the ability to isolate and culture human biliary epithelial c...

    journal_title:Clinics in liver disease

    pub_type: 杂志文章,评审

    doi:10.1016/s1089-3261(03)00093-x

    authors: Mayo MJ

    更新日期:2003-11-01 00:00:00

  • Telaprevir: hope on the horizon, getting closer.

    abstract::Standard therapy with pegylated interferon and ribavirin for chronic hepatitis C is effective in 40% to 50% of individuals with genotype 1 hepatitis C virus (HCV) infection and is associated with significant treatment-related toxicities. Newly developed small molecules that target key enzymes essential for HCV replica...

    journal_title:Clinics in liver disease

    pub_type: 杂志文章,评审

    doi:10.1016/j.cld.2009.05.009

    authors: Weisberg IS,Jacobson IM

    更新日期:2009-08-01 00:00:00

  • Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability.

    abstract::Liver cancer is the second leading cause of global cancer mortality. The major risk factors for hepatocellular carcinoma (HCC) are being addressed with success by prevention efforts. Vaccination against hepatitis B virus has reduced incidence of HCC in Taiwan and is partly responsible for lower rates in China. New inf...

    journal_title:Clinics in liver disease

    pub_type: 杂志文章,评审

    doi:10.1016/j.cld.2015.01.001

    authors: McGlynn KA,Petrick JL,London WT

    更新日期:2015-05-01 00:00:00

  • Autoimmune hepatitis: diagnostic criteria, subclassifications, and clinical features.

    abstract::The diagnosis of AIH depends on the finding of several suggestive features together with careful exclusion of liver diseases of other etiologies. Wherever possible, the diagnosis should be confirmed histologically by an experienced hepatopathologist. Seronegativity for the conventional autoantibodies at presentation d...

    journal_title:Clinics in liver disease

    pub_type: 杂志文章,评审

    doi:10.1016/s1089-3261(02)00019-3

    authors: McFarlane IG

    更新日期:2002-08-01 00:00:00

  • The role of the transjugular intrahepatic portal-systemic shunt in the management of variceal bleeding.

    abstract::For patients who present with variceal bleeding refractory to endoscopic and pharmacologic methods, TIPS is a new and effective therapy. Stents are used in selected patients with decompensated liver disease and those who anticipate liver transplantation within 6 to 12 months. Surveillance of TIPS with ultrasound, with...

    journal_title:Clinics in liver disease

    pub_type: 杂志文章,评审

    doi:10.1016/s1089-3261(05)70257-9

    authors: Faust TW,Sorrell MF

    更新日期:1997-05-01 00:00:00

  • HBV/HCV Coinfection in the Era of HCV-DAAs.

    abstract::Epidemiologic studies suggest that 10% to 15% of patients infected with hepatitis C virus (HCV) are coinfected with hepatitis B virus (HBV) in the United States as a result of the shared modality of transmission, but the true prevalence is not known. The progression of liver disease to cirrhosis and hepatocellular car...

    journal_title:Clinics in liver disease

    pub_type: 杂志文章,评审

    doi:10.1016/j.cld.2019.04.003

    authors: Abdelaal R,Yanny B,El Kabany M

    更新日期:2019-08-01 00:00:00